Browse Conditions Browse Medicines

NICE publish draft quality standard update for lung cancer

For Lung cancer (Non-Small Cell)

The National Institute for Health and Care Excellence (NICE) have published the draft of their updated quality standard for lung cancer.

The quality standard covers diagnosing and managing lung cancer in adults. It describes high-quality care in priority areas for improvement and is now open for consultation.

The standard is for:
  • the public
  • commissioners
  • health service providers
  • health, public health and social care practitioners
Quality standard consultation
You can now comment on this draft quality standard.

Closing date for comments: Friday 23 August 2019 at 5pm

Quality statements
  • Statement 1 Local authorities and their partners use coordinated campaigns to raise awareness of the symptoms and signs of lung cancer and encourage people to seek medical advice if they need to. [2012, updated 2019]
  • Statement 2 Adults with suspected or confirmed lung cancer who smoke are referred to an evidence-based stop smoking service. [new 2019]
  • Statement 3 Adults with suspected or confirmed lung cancer have access to a named lung cancer clinical nurse specialist. [2012, updated 2019]
  • Statement 4 Adults with lung cancer have investigations to complete diagnostic staging and assess lung function before starting treatment with curative intent. [new 2019]
  • Statement 5 Adults with non-small-cell lung cancer stage IIIb, IIIc or IV who are having tissue samples taken, have them taken in a suitable form for pathological diagnosis and assessment of predictive biomarkers. [2012, updated 2019]
  • Statement 6 Adults with non-small-cell lung cancer stage I or II and good performance status have treatment with curative intent. [new 2019]

© NICE [2019]

Lung cancer (update) In development [GID-QS10132]. Expected publication date: 13 December 2019
Available from: See Link below. All rights reserved. Subject to Notice of rights
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

The information provided by NICE was accurate at the time this article was issued.

NICE lung cancer quality standard information

Reporting of suspected adverse reactions

Reporting suspected adverse reactions (side effects) after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals or patients are asked to report any suspected adverse reactions via the Yellow Card Scheme at or search for MHRA Yellow Card in the Google Play or Apple App Store.

Disclaimer: This site is designed to offer information for general educational purposes only. The health information furnished on this site and the interactive responses are not intended to be professional advice and are not intended to replace personal consultation with a qualified physician, pharmacist, or other healthcare professional. We cannot provide individual medical advice. You must always seek the advice of a professional for questions related to a disease, disease symptoms, and appropriate therapeutic treatments.

About condition